Close Menu

financial guidance

The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.

Due to a ransom cyberattack on its information technology systems, the firm reported full revenue but only preliminary earnings estimates.

The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.

The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.

OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.

The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.

The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.

The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.

The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.

The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.